A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Participants With KRASG12C Mutant Advanced Solid Tumors
This is a study evaluating the safety, pharmacokinetics, and efficacy of MK-1084 alone, and MK-1084 plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral